Tomoyuki Abe, Hiroshi Sakagami, Shigeru Amano, Shin Uota, Kenjiro Bandow, Yoshihiro Uesawa, Shiori U, Hiroki Shibata, Yuri Takemura, Yu Kimura, Koichi Takao, Yoshiaki Sugita, Akira Sato, Sei-Ichi Tanuma, Hiroshi Takeshima
Background. Many anti-cancer drugs used in clinical practice cause adverse events such as oral mucositis, neurotoxicity, and extravascular leakage. We have reported that two 3-styrylchromone derivatives, 7-methoxy-3-[(1 E )-2-phenylethenyl]-4 H -1-benzopyran-4-one (Compound A ) and 3-[(1 E )-2-(4-hydroxyphenyl)ethenyl]-7-methoxy-4 H -1-benzopyran-4-one (Compound B ), showed the highest tumor-specificity against human oral squamous cell carcinoma (OSCC) cell lines among 291 related compounds. After confirming their superiority by comparing their tumor specificity with newly synthesized 65 derivatives, we investigated the neurotoxicity of these compounds in comparison with four popular anti-cancer drugs...
July 14, 2023: Medicines (Basel, Switzerland)